INTACT: a randomised feasibility study of INtravenous iron versus usual care to Treat Anaemia in CriTical care survivors
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2019
Price : $35 *
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms INTACT
- 22 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Jul 2018 New trial record
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.